Prostate cancer with homologous recombination repair gene mutations and PARP inhibitors: clinical progress / 中华泌尿外科杂志
Chinese Journal of Urology
;
(12): 397-400, 2021.
Artículo
en Chino
| WPRIM
| ID: wpr-885033
ABSTRACT
DNA damage repair gene mutations are prevalent in advanced prostate cancer. Among these, mutations in homologous recombination repair genes could impair the ability of cell to restore the DNA double-strand break, which can be exploited by Poly-ADP-ribose polymerase (PARP) inhibitors through synthetic lethality and result in cell death. The phase Ⅲ study " PROfound" showed that the PAPR inhibitor Olaparib could significantly improve the survival of patients with homologous recombination repair gene mutations compared with novel hormone agents, starting the era of targeted, precise and individualized treatment based on genetic profile detection for prostate cancer treatment.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Chinese Journal of Urology
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS